
IDEXX Laboratories (IDXX) Stock Forecast & Price Target
IDEXX Laboratories (IDXX) Analyst Ratings
Bulls say
IDEXX Laboratories has established a robust customer retention rate of approximately 97%, enhancing the predictability of its revenue and earnings streams. The company has also achieved a compounded annual growth rate (CAGR) of around 16% in organic consumables recurring revenue from 2016 to 2022, showcasing its ability to drive consistent revenue growth. Additionally, customers that utilize the full suite of IDEXX's offerings experience 3.5 times higher growth across various testing categories, indicating the potential for accelerated adoption and market expansion as pet patient visits recover.
Bears say
IDEXX Laboratories has reported a consecutive decline in clinical vet visits for three consecutive quarters, culminating in a year-over-year decrease of 1.7% in Q4'25, which raises concerns over the demand for its diagnostic products and services. The company anticipates a further decline of 200 basis points in end market pet visits in 2026, primarily attributed to economic pressures on lower-income pet owners, potentially restricting demand for IDEXX's offerings. Furthermore, any adverse developments regarding product lines or economic hardships affecting customers may exacerbate revenue slowdowns, placing additional strain on the company's financial outlook.
This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.
IDEXX Laboratories (IDXX) Analyst Forecast & Price Prediction
Start investing in IDEXX Laboratories (IDXX)
Order type
Buy in
Order amount
Est. shares
0 shares